Abl (Q252H), active

N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).

Catalog No. Size Price Quantity
14-751M 250 µg $2466.85
14-751 10 µg $387.28

For account specific pricing, please contact Customer Service at customerservicedrx@eurofins.com.

Related Family Members:

Target
Abl
Expression System
Expressed by baculovirus in Sf21 insect cells
Application
Kinase Assay
Molecular Weight
121kDa
Accession Number
NM_005157.3; NM_007313.2
Species
Human
Tag
6His
Purity
Purity 51% by SDS-PAGE and Coomassie staining.
Purification Method
Ni2+/NTA-agarose
Content
Protein in 50 mM Tris/HCl pH7.5, 150 mM NaCl, 270 mM sucrose, 1 mM benzamidine, 0.2 mM PMSF, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij 35. Frozen solution.
Storage
6 months at -70°C
Bulk Sizes
Inquire